Aktuellt
SENASTE
Redeye provides its initial take on Scandion Oncology's Q1 2024 report. The company's first-quarter burn rate broadly aligned with our expectations and we understand that it is well on its way to run CORIST part 3 expansion cohorts. We will await the final terms of the company's recently announced rights issue to adjust our estimates and valuation. Thus, we will revert with our quarterly update after Scandion publishes final terms in the coming days.
LÄS MER
